Treatment of Primary CNS Lymphoma With High-Dose Methotrexate in Immunocompetent Pediatric Patients

被引：15
|
作者：
Shah, Amish C. [1 ]
Kelly, David R. [2 ]
Nabors, L. Burt [3 ]
Oakes, W. Jerry [4 ]
Hilliard, Lee M. [5 ]
Reddy, Alyssa T. [3 ,4 ,5 ]
机构：
[1] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA
[2] Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Neurol, Sch Med, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA
[5] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA
来源：
PEDIATRIC BLOOD & CANCER | 2010年 / 55卷 / 06期
关键词：
anaplastic large cell lymphoma; diffuse large B-cell lymphoma; methotrexate; primary central nervous system lymphoma; CENTRAL-NERVOUS-SYSTEM; LONG-TERM SURVIVAL; THERAPEUTIC MANAGEMENT; EPIDEMIOLOGY;
D O I：
10.1002/pbc.22752
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report two cases of primary CNS lymphoma (PCNSL) treated with high-close methotrexate. Though standard adult treatment of PCNSL incorporates whole-brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients. Studies in adults indicate methotrexate therapy can be effective against PCNSL and has advantages over the current standard of treatment. Both patients have no evidence of disease 9 and 7 years after treatment, suggesting high-close methotrexate may lead to disease control in pediatric patients with PCNSL while avoiding the effects of radiotherapy. Pediatr Blood Cancer. 2010;55:1227-1230. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码：1227 / 1230
页数：4
相关论文
共 50 条
  • [41] High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
    Fritsch, K.
    Kasenda, B.
    Schorb, E.
    Hau, P.
    Bloehdorn, J.
    Moehle, R.
    Loew, S.
    Binder, M.
    Atta, J.
    Keller, U.
    Wolf, H-H
    Krause, S. W.
    Hess, G.
    Naumann, R.
    Sasse, S.
    Hirt, C.
    Lamprecht, M.
    Martens, U.
    Morgner, A.
    Panse, J.
    Frickhofen, N.
    Roeth, A.
    Hader, C.
    Deckert, M.
    Fricker, H.
    Ihorst, G.
    Finke, J.
    Illerhaus, G.
    LEUKEMIA, 2017, 31 (04) : 846 - 852
  • [42] Impact of Anticonvulsant - Methotrexate Interactions on High Dose Methotrexate Clearance and Outcomes in Patients with Primary CNS Lymphoma
    Cypes, Illana N.
    Mier-Hicks, Angel
    Scott, Jordan
    Groman, Adrienne
    Torka, Pallawi
    Gawronski, Catherine
    Przespolewski, Eugene
    BLOOD, 2021, 138
  • [43] Phase II study of high-dose methotrexate, thiotepa, vincristine and dexamethasone for primary CNS lymphoma.
    Sohn, HJ
    Ahn, JH
    Ryu, MH
    Kim, SE
    Choi, SJ
    Chang, HM
    Kim, TW
    Lee, JS
    Kim, WG
    Kang, YK
    BLOOD, 2003, 102 (11) : 292B - 292B
  • [44] High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma
    Kiewe, Philipp
    Loddenkemper, Christoph
    Anagnostopoulos, Ioannis
    Reinwald, Mark
    Thiel, Eckhard
    Korfel, Agnieszka
    NEURO-ONCOLOGY, 2007, 9 (02) : 96 - 102
  • [45] NOA-03 multicenter trial of high-dose methotrexate in primary CNS lymphoma:: Final report
    Herrlinger, U
    Küker, W
    Uhl, M
    Blaicher, HP
    Karnath, HO
    Kanz, L
    Bamberg, M
    Weller, M
    NEURO-ONCOLOGY, 2005, 7 (03) : 400 - 400
  • [46] Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate
    Choi, Yun Jung
    Park, Hyangmin
    Lee, Ji Sung
    Lee, Ju-Yeon
    Kim, Shin
    Kim, Tae Won
    Park, Jung Sun
    Kim, Jeong Eun
    Yoon, Dok Hyun
    Suh, Cheolwon
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 504 - 509
  • [47] Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma
    Schaff, Lauren R.
    Carlow, Dean
    Schofield, Ryan
    Wongchai, Venissala
    Madzsar, Juli
    Hyde, Allison
    Reiner, Anne S.
    Panageas, Katherine S.
    Deangelis, Lisa M.
    Mellinghoff, Ingo K.
    Lobbous, Mina
    Nabors, Louis B.
    Grommes, Christian
    JCO ONCOLOGY PRACTICE, 2024, 20 (10)
  • [48] The role of thiotepa in the High-dose Chemotherapy in primary CNS Lymphoma
    Ortner, Petra
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (01)
  • [49] Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.
    Lindhorst, Scott Michael
    McSherry, Frances
    Desjardins, Annick
    Friedman, Henry S.
    Peters, Katherine B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL)
    Ferreri, A. J.
    Foppoli, M.
    Martelli, M.
    Pangalis, G.
    Frezzato, M.
    Cabras, G.
    Fabbri, A.
    Corazzelli, G.
    Ilariucci, F.
    Rossi, G.
    Soffietti, R.
    Stelitano, C.
    Vallisa, D.
    Zaja, F.
    Zoppegno, L.
    Aondio, G.
    Annibali, O.
    Balzarotti, M.
    Brandes, A.
    Fajardo, J.
    Gomez, H.
    Guarini, A.
    Pinotti, G.
    Rigacci, L.
    Uhlmann, C.
    Ponzoni, M.
    Reni, M.
    Zucca, E.
    Cavalli, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 104 - 104
12345